X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (7596) 7596
Magazine Article (20) 20
Book Chapter (9) 9
Web Resource (2) 2
Book Review (1) 1
Conference Proceeding (1) 1
Dissertation (1) 1
Publication (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (6103) 6103
male (3794) 3794
female (3520) 3520
indoles - therapeutic use (3298) 3298
indoles - adverse effects (3232) 3232
middle aged (2744) 2744
aged (2130) 2130
adult (2127) 2127
animals (1856) 1856
indoles - administration & dosage (1727) 1727
indoles - pharmacology (1615) 1615
oncology (1557) 1557
treatment outcome (1330) 1330
pharmacology & pharmacy (1303) 1303
antineoplastic agents - adverse effects (973) 973
pyrroles - adverse effects (938) 938
cancer (927) 927
sunitinib (860) 860
pyrroles - therapeutic use (858) 858
antineoplastic agents - therapeutic use (853) 853
double-blind method (743) 743
dose-response relationship, drug (738) 738
carcinoma, renal cell - drug therapy (709) 709
care and treatment (700) 700
kidney neoplasms - drug therapy (673) 673
aged, 80 and over (665) 665
mice (651) 651
rats (604) 604
indoles - pharmacokinetics (581) 581
analysis (550) 550
efficacy (537) 537
drug therapy (521) 521
research (489) 489
pyrroles - administration & dosage (488) 488
medicine & public health (486) 486
sulfonamides - adverse effects (473) 473
therapy (466) 466
double-blind (458) 458
time factors (452) 452
safety (434) 434
adolescent (420) 420
drug therapy, combination (413) 413
metastasis (401) 401
tyrosine kinase inhibitor (399) 399
kidney neoplasms - pathology (396) 396
neurosciences (390) 390
chemotherapy (388) 388
drug administration schedule (386) 386
niacinamide - analogs & derivatives (385) 385
expression (381) 381
clinical trials as topic (368) 368
antineoplastic agents - administration & dosage (366) 366
disease-free survival (365) 365
risk factors (364) 364
antineoplastic agents (358) 358
clinical neurology (357) 357
endothelial growth-factor (354) 354
survival (352) 352
clinical trials (351) 351
sulfonamides - therapeutic use (351) 351
administration, oral (350) 350
melanoma - drug therapy (350) 350
medicine, general & internal (349) 349
protein kinase inhibitors - adverse effects (347) 347
tumors (339) 339
antimitotic agents (332) 332
retrospective studies (329) 329
pharmacokinetics (322) 322
neoplasms - drug therapy (317) 317
health aspects (316) 316
young adult (314) 314
antineoplastic combined chemotherapy protocols - therapeutic use (313) 313
prospective studies (311) 311
melanoma (308) 308
apoptosis (306) 306
bevacizumab (306) 306
urology & nephrology (306) 306
protein kinase inhibitors - therapeutic use (304) 304
indoles - chemistry (301) 301
indoles (298) 298
interferon-alpha (298) 298
indole (297) 297
sorafenib (294) 294
disease models, animal (291) 291
pharmacology/toxicology (285) 285
mutation (283) 283
cell line, tumor (280) 280
angiogenesis (276) 276
abridged index medicus (274) 274
angiogenesis inhibitors - adverse effects (269) 269
antineoplastic combined chemotherapy protocols - adverse effects (268) 268
hypertension (268) 268
angiogenesis inhibitors - therapeutic use (265) 265
biochemistry & molecular biology (265) 265
neoplasm metastasis (262) 262
carcinoma, renal cell - pathology (254) 254
internal medicine (254) 254
trial (253) 253
toxicity (251) 251
follow-up studies (249) 249
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (7279) 7279
German (109) 109
French (80) 80
Japanese (77) 77
Russian (47) 47
Spanish (35) 35
Chinese (26) 26
Dutch (15) 15
Danish (14) 14
Italian (14) 14
Czech (9) 9
Hungarian (9) 9
Portuguese (9) 9
Norwegian (4) 4
Polish (4) 4
Swedish (4) 4
Romanian (2) 2
Finnish (1) 1
Hebrew (1) 1
Korean (1) 1
Lithuanian (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
JNCI : Journal of the National Cancer Institute, ISSN 0027-8874, 2012, Volume 104, Issue 2, pp. 93 - 113
.... This has raised challenges in the management of adverse events (AEs) associated with the six targeted agents approved in RCC-sorafenib, sunitinib, pazopanib, bevacizumab... 
TYROSINE KINASE INHIBITORS | CONTROLLED-TRIAL | INTERFERON-ALPHA | SUNITINIB TREATMENT | CANCER-PATIENTS | VENOUS THROMBOEMBOLISM | ONCOLOGY | HEART-FAILURE | DOUBLE-BLIND | EXPANDED ACCESS PROGRAM | ENDOTHELIAL GROWTH-FACTOR | Niacinamide - analogs & derivatives | Hypothyroidism - chemically induced | Pneumonia - therapy | Anorexia - therapy | Humans | Drug Eruptions - therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Kidney Neoplasms - metabolism | Phenylurea Compounds | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Weight Loss - drug effects | Benzenesulfonates - adverse effects | Bevacizumab | TOR Serine-Threonine Kinases - antagonists & inhibitors | Pyridines - adverse effects | Antineoplastic Agents - adverse effects | Pneumonia - chemically induced | Pyrroles - adverse effects | Antineoplastic Agents - pharmacology | Carcinoma, Renal Cell - drug therapy | Everolimus | Hypothyroidism - therapy | Wound Healing - drug effects | Molecular Targeted Therapy - methods | Sirolimus - adverse effects | Antibodies, Monoclonal, Humanized - adverse effects | Sirolimus - analogs & derivatives | Europe | Gastrointestinal Tract - drug effects | Cardiovascular System - drug effects | Evidence-Based Medicine | Carcinoma, Renal Cell - metabolism | Indoles - adverse effects | Pyrimidines - adverse effects | Sulfonamides - adverse effects | Anorexia - chemically induced | Kidney Neoplasms - drug therapy | Protein-Tyrosine Kinases - antagonists & inhibitors | Antimitotic agents | Drugs | Complications and side effects | Care and treatment | Adverse and side effects | Carcinoma, Renal cell | Research | Drug therapy | Antineoplastic agents
Journal Article
The oncologist (Dayton, Ohio), ISSN 1549-490X, 2017, Volume 22, Issue 7, pp. 823 - 833
Tremendous progress has been made in the clinical landscape of advanced‐stage BRAF V600–mutant melanoma treatment over the past 5 years. Targeted therapies... 
BRAF | Mitogen‐activated protein kinase signaling system | Drug‐related side effects and adverse reactions | Protein kinase inhibitors | Melanoma | Mitogen-activated protein kinase signaling system | Drug-related side effects and adverse reactions | IMPROVED SURVIVAL | PHASE-3 | COMBINATION | COMBINED DABRAFENIB | THERAPY | MEK INHIBITION | ONCOLOGY | DOUBLE-BLIND | COBIMETINIB | BRAF-MUTANT MELANOMA | VEMURAFENIB | Oximes - adverse effects | Humans | Fever - therapy | Oximes - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Carbamates - administration & dosage | Protein Kinase Inhibitors - adverse effects | Fever - chemically induced | Pyridones - administration & dosage | Benzimidazoles - administration & dosage | Antineoplastic Agents - adverse effects | Benzimidazoles - adverse effects | Skin Diseases - chemically induced | Piperidines - administration & dosage | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Azetidines - adverse effects | Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors | Melanoma - pathology | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Vemurafenib | Azetidines - administration & dosage | Indoles - adverse effects | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Piperidines - adverse effects | Sulfonamides - adverse effects | Carbamates - adverse effects | Pyrimidinones - administration & dosage | Pyridones - adverse effects | Sulfonamides - administration & dosage | Melanoma and Cutaneous Malignancies
Journal Article
Journal of the American Academy of Dermatology, ISSN 0190-9622, 2008, Volume 58, Issue 4, pp. 545 - 570
Chemotherapeutic agents give rise to numerous well described adverse effects that may affect the skin, hair, mucous membranes, or nails... 
Dermatology | CELL LUNG-CANCER | CHRONIC MYELOGENOUS LEUKEMIA | GROWTH-FACTOR RECEPTOR | PEGYLATED LIPOSOMAL DOXORUBICIN | PHASE-II TRIAL | RADIATION-RECALL DERMATITIS | CHRONIC LYMPHOCYTIC-LEUKEMIA | TYROSINE-KINASE INHIBITOR | CHRONIC MYELOID-LEUKEMIA | HAND-FOOT SYNDROME | DERMATOLOGY | Erlotinib Hydrochloride | Niacinamide - analogs & derivatives | Drug Eruptions - pathology | Humans | Antibodies, Monoclonal - adverse effects | Phenylurea Compounds | Protein Kinase Inhibitors - adverse effects | Benzenesulfonates - adverse effects | Antibodies, Monoclonal, Humanized | Pyridines - adverse effects | Fusion Proteins, bcr-abl | Antineoplastic Agents - adverse effects | Nail Diseases - chemically induced | Drug-Related Side Effects and Adverse Reactions | Hair Diseases - chemically induced | Pyrroles - adverse effects | Mucous Membrane - drug effects | Cetuximab | Taxoids - adverse effects | Platinum Compounds - adverse effects | Drug Eruptions - etiology | Skin Diseases - chemically induced | Imatinib Mesylate | Piperazines - adverse effects | Antimetabolites - adverse effects | Indoles - adverse effects | Signal Transduction - drug effects | Pyrimidines - adverse effects | Quinazolines - adverse effects | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Benzamides | Proteasome Inhibitors | Skin - drug effects | Protein-Tyrosine Kinases - antagonists & inhibitors | Chemotherapy | Platelet-derived growth factor | Formulae, receipts, prescriptions | Dermatologic agents | Lung cancer, Non-small cell | Cancer | Index Medicus
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 10/2018, Volume 2018, Issue 10, p. CD007360
...) have been reported, making this update relevant. Objectives To evaluate the effects of naftopidil for the treatment of LUTS associated with BPH... 
Piperazines | Plant Extracts | Benzilates | Adrenergic alpha‐Antagonists | Urology | Alpha‐blockers/Alpha‐1 adrenoceptors/Alpha antagonists/5‐alpha reductase inhibitors | Naphthalenes | Randomized Controlled Trials as Topic | Prostatic Hyperplasia | Urological Agents | Tamsulosin | Lower Urinary Tract Symptoms | Sulfonamides | Quality of Life | Prostatism | Benign prostatic hyperplasia | Treatment of Benign Prostatic Hyperplasia | Ethamsylate | Indoles | Pharmacologic/Medical Therapies | Medicine General & Introductory Medical Sciences | Drug Combinations | Naftopidil | Benign Prostatic Hyperplasia/Obstruction (Hypertrophy, Prostatic Hyperplasia) | Naphthalenes [adverse effects; therapeutic use] | 75 MG | EFFICACY | Prostatic Hyperplasia [complications] | STORAGE SYMPTOM | SEXUAL FUNCTION | CLINICAL PROGRESSION | MEDICINE, GENERAL & INTERNAL | OVERACTIVE BLADDER | Sulfonamides [adverse effects; therapeutic use] | Piperazines [adverse effects; therapeutic use] | ALPHA-ADRENOCEPTOR ANTAGONISTS | Adrenergic alpha-Antagonists [adverse effects; therapeutic use] | Prostatism [drug therapy; etiology] | TAMSULOSIN HYDROCHLORIDE | ALPHA-1 BLOCKERS | HEALTH-STATUS | Benzilates - adverse effects | Naphthalenes - adverse effects | Benzilates - therapeutic use | Humans | Adrenergic alpha-Antagonists - therapeutic use | Male | Prostatic Hyperplasia - complications | Prostatism - drug therapy | Urological Agents - adverse effects | Adrenergic alpha-Antagonists - adverse effects | Ethamsylate - therapeutic use | Lower Urinary Tract Symptoms - drug therapy | Lower Urinary Tract Symptoms - etiology | Ethamsylate - adverse effects | Urological Agents - therapeutic use | Prostatism - etiology | Tamsulosin - adverse effects | Tamsulosin - therapeutic use | Piperazines - therapeutic use | Piperazines - adverse effects | Indoles - adverse effects | Sulfonamides - therapeutic use | Sulfonamides - adverse effects | Indoles - therapeutic use | Plant Extracts - therapeutic use | Naphthalenes - therapeutic use | Plant Extracts - adverse effects
Journal Article
Clinical journal of the American Society of Nephrology, ISSN 1555-9041, 01/2017, Volume 12, Issue 1, pp. 176 - 189
Journal Article
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2015, Volume 372, Issue 1, pp. 30 - 39
In patients with melanomas containing activating BRAF mutations, the combination of a BRAF inhibitor and a MEK inhibitor improved overall survival, as compared... 
CRITERIA | BRAF-MUTATED MELANOMA | METASTATIC MELANOMA | RAF INHIBITION | MEDICINE, GENERAL & INTERNAL | MEK INHIBITION | ACQUIRED-RESISTANCE | V600E MUTATION | TUMORS | OVERCOME | VEMURAFENIB | Skin Neoplasms - drug therapy | Oximes - adverse effects | Humans | Middle Aged | Oximes - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Male | Protein Kinase Inhibitors - adverse effects | Young Adult | Pyridones - administration & dosage | Aged, 80 and over | Adult | Female | Skin Neoplasms - pathology | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Kaplan-Meier Estimate | Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors | Melanoma - secondary | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Protein Kinase Inhibitors - administration & dosage | Indoles - adverse effects | Sulfonamides - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Adolescent | Intention to Treat Analysis | Survival Analysis | Sulfonamides - adverse effects | Indoles - therapeutic use | Aged | Pyrimidinones - administration & dosage | Mutation | Pyridones - adverse effects | Melanoma - mortality | Patients | Health aspects | Risk factors | Melanoma | Toxicity | Medical treatment | MEK inhibitors | Antitumor activity | Metastasis | Kinases | Cancer therapies | Clinical outcomes | Metastases | Index Medicus | Abridged Index Medicus
Journal Article